Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

homoharringtonine

homoharringtonine is a protein synthesis inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — homoharringtonine
Class
—
Route
—
Patents
0
Programs
3
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

homoharringtonine is a protein synthesis inhibitor.

Key facts

INN homoharringtonine
Mechanism Protein synthesis inhibitor

Mechanism of action

Protein synthesis inhibitor

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. DAC-HAAG-02 Phase 3 · Hospital Authority · Acute Myeloid Leukemia
  2. Homoharringtonine Phase 2 · Teva Pharma · Myeloid Leukemia, Chronic
  3. Venetoclax；Azacitidine；Homoharringtonine Phase 2 · First People's Hospital · Secondary Acute Myeloid Leukemia

Frequently asked questions

What is homoharringtonine?

homoharringtonine is a protein synthesis inhibitor.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.